CVSA
Covista Inc.
NYSE: CVSA · CONSUMER DEFENSIVE · EDUCATION & TRAINING SERVICES
$128.73
+0.16% today
Updated 2026-06-02
Market cap
$4.40B
P/E ratio
18.84
P/S ratio
2.31x
EPS (TTM)
$6.87
Dividend yield
—
52W range
$87 – $156
Volume
0.3M
Covista Inc. (CVSA) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed CVSA price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$128.73
Today
Analyst consensus
$155.00
+20.41% · 12M
2030 Base
$142.17
+10.44% future
NPV today
$100.13
@ 8% WACC
6 analysts:
2 Buy2 Hold0 Sell
Management guidance
CVSA raised FY2026 revenue guidance to $1.98B (from prior $1.89B TTM) and adjusted EPS to $7.95-$8.15, representing 10.61% YoY revenue growth. Management has signaled continued expansion of Chamberlain University (25 campuses including new Cincinnati location opening Fall 2026) and AI-powered healthcare education initiatives, but has not provided explicit multi-year revenue targets beyond FY2026.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
CVSA · Covista Inc. · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$142.17
NPV today: $100.13
Base case (2030)
$142.17
NPV today: $100.13
Bull case (2030)
$245.17
NPV today: $172.68
WallStSmart.com
CVSA financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | $2.0B | $2.3B | $2.7B | $3.1B | $3.6B |
| Revenue growth | 12.9% | 10.6% | 16.7% | 17.8% | 15.8% | 13.9% |
| Net margin | — | 14.0% | 14.4% | 14.6% | 14.8% | 14.7% |
| EPS | $4.18 | $8.07 | $9.65 | $11.52 | $13.40 | $15.18 |
| Diluted shares | — | 34M | 34M | 35M | 35M | 35M |
| Net debt | — | $-196.61M | $-425.99M | $-696.08M | $-1.01B | $-1.37B |
| P/S multiple | — | 1.0x | 1.0x | 1.0x | 1.0x | 1.0x |
| Implied price (base) | — | $63.58 | $79.52 | $98.79 | $119.79 | $142.17 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $3.6B | $3.6B | $3.6B |
| P/S multiple | 1.0x | 1.0x | 2.0x |
| Diluted shares | 35M | 35M | 35M |
| Net debt | $-1.37B | $-1.37B | $-1.37B |
| Implied P/E † | 9x | 9x | 16x |
| 2030 Price | $142.17 | $142.17 | $245.17 |
| NPV @ 8% | $100.13 | $100.13 | $172.68 |
† Implied P/E: Multiples remain elevated across all three scenarios because CVSA is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $142.17 base case
CVSA catalysts and risks
Growth catalysts
+ Chamberlain University campus expansion (25 locations as of 2026, growth runway to 30+ campuses by 2029)
+ AI-powered classroom initiatives (Google Cloud partnership announced Apr 2026) driving student engagement and retention
+ Healthcare workforce shortage tailwinds (permanent structural growth in medical, nursing, PA education demand)
+ Medical school residency placement rates (97% first-time attainment suggests quality premium pricing power)
+ Strategic focus on profitable healthcare education verticals post-rebranding from Adtalem (Feb 2026)
Key risks
- Regulatory risk: Higher education enrollment and accreditation subject to federal/state policy changes; loan forgiveness programs could disrupt demand
- Competition: Stride, Grand Canyon Education, and TAL Education compete aggressively in healthcare education; talent retention in competitive hiring market
- Macro sensitivity: Economic downturn could reduce discretionary education spending despite healthcare wage growth tailwinds
- Technology execution risk: AI classroom platform adoption rates and monetization model unproven at scale
- Margin compression: High operating leverage model (19.4% oper. margin) vulnerable to cost inflation and pricing pressure
Methodology · Covista Inc. 2030 stock forecast model
Covista Inc. 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 6 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for CVSA by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-1.37B by 2030) |
| 3. Time value | NPV calculated using 8% WACC (CAPM: beta 0.627) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 1.0x / bull 2.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 21, 2026.
CVSA price target FAQ
What is the CVSA price target for 2030?
WallStSmart's Covista Inc. 2030 base case is $142.17 per share, with a bull case of $245.17 and bear case of $142.17. The NPV of the base case discounted to today at 8% WACC is $100.13.
How is the Covista Inc. 2030 stock forecast calculated?
The CVSA 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the CVSA price target account for dilution?
Covista Inc. is projected to grow diluted share count from 34M to 35M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on CVSA stock?
6 analysts cover CVSA with an average 12-month price target of $155.00. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.